Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Immix Biopharma, Inc.NASDAQ: IMMX

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$78.21M, compared with -$14.86M a year earlier.

Context

  • Net debt amounted to 81.6% of total assets at the end of Q1 FY2026, up 6.9 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -426.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$78.21M+15.8% QoQ
Last fiscal yearDec 2025
-$92.86M-459.1% YoY
Year agoMar 2025
-$14.86M-426.3% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-426.3%——
1 year-459.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(92.86M) USD
Year-over-year change
-459.1%

Net Debt vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -426.3% is the 8th highest of 11, against a peer median of +41.5%.
  • Net debt amounts to 81.6% of total assets for IMMX, versus a peer median of 32.3%.
IMMX Competitors
Net Debt for IMMX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRDFCardiff Oncology, Inc.Mar 2026-$7.9M USD+65.3%—16.1%
CLDXCelldex Therapeutics, Inc.Sep 2026-$17.08M USD+48.9%—2.4%
CTMXCytomX Therapeutics, Inc.Mar 2026-$25.97M USD+34.2%—7.2%
NBPNovaBridge BiosciencesDec 2025-$29.67M USD+93.7%—79.7%
MGNXMacroGenics, Inc.Mar 2026-$30.01M USD+72.2%—13.8%
RCUSArcus Biosciences, Inc.Jun 2026-$36M USD+74.1%—3.9%
IMMPImmutep LimitedDec 2025-A$71.54M AUD+0.9%—48.6%
IMMXImmix Biopharma, Inc.Mar 2026-$78.21M USD-426.3%—81.6%
IMUXImmunic, Inc.Mar 2026-$186.21M USD-1297.0%—98.1%
ABVXAbivax S.A.Jun 2026-€386.78M EUR-1737.1%—83.7%
NRIXNurix Therapeutics, Inc.Aug 2026-$654.91M USD-2883.4%—54.8%
Peer median (excluding IMMX) —+41.5%—32.3%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.64M13.44M17.51M17.68M93.93M
Short-term Investments00006.48M
Net Receivables25.72K255.71K1.17M1.97M0
Inventory00000
Other Current Assets516.19K78.07K44.58K32.27K150.72K
Total Current Assets18.19M14.9M19.79M20.2M101.24M
Property, Plant & Equipment (Net)5.7K3.56K50.18K2.73M3.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets(0)6.72K87.23K20.42K114.05K
Total Non-current Assets5.7K10.28K137.41K2.75M3.6M
Total Assets18.19M14.91M19.93M22.95M104.84M
Account Payables142.94K143.07K1.43M5.39M5.44M
Short-term Debt50K0000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000658.16K0
Total Current Liabilities202.04K1.27M3.72M8.69M10.11M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0475K000
Total Non-current Liabilities0475K01.01M933.63K
Total Liabilities202.04K1.75M3.72M9.7M11.04M
Common Stock1.32K1.4K2K2.76K5.3K
Retained Earnings(29.76M)(37.99M)(53.41M)(75.02M)(104.46M)
Accumulated OCI125.41K87.02K134.67K(1.06K)60.16K
Other Stockholders Equity00000
Minority Interest00(201.74K)00
Total Equity17.99M13.16M16.2M13.25M93.8M
Total Debt50K001.07M1.07M
Net Debt(17.59M)(13.44M)(17.51M)(16.61M)(92.86M)

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.